Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Bardou

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 14, 2007
In vitro and in vivo pharmacological characterization of ethyl-4-[trans-4-[((2S)-2-hydroxy-3-[4-hydroxy-3[(methylsulfonyl)amino]-phenoxy]propyl) amino]cyclohexyl]benzoate hydrochloride (SAR150640), a new potent and selective human beta3-adrenoceptor agonist for the treatment of preterm laborTiziano Croci, Roberto Cecchi, Pietro Marini, et al.
BMC Proceedings|August 28, 2025
Accelerating HPV-related cancer elimination - a meeting reportF Ricardo Burdier, F Xavier Bosch, Dur-E-Nayab Waheed, et al.
European Journal of Medical Genetics|March 24, 2025
Lack of behavioural improvement with sirolimus in a patient with MTOR-related macrocephaly with pigmentary mosaicism: A new case reportBertille Bonniaud, Maxime Luu, Coline Cormier, et al.
The Pharmacogenomics Journal|May 19, 2022
Exome sequencing allows detection of relevant pharmacogenetic variants in epileptic patientsSimon Verdez, Quentin Thomas, Philippine Garret, et al.
Therapie|January 2, 2022
Health crisis: What opportunities for clinical drug research?Dominique Deplanque, Stanislas Cviklinski, Marc Bardou, et al.
Therapie|December 20, 2021
Dominique Deplanque, Stanislas Cviklinski, Marc Bardou, et al.
BMJ Open|November 20, 2024
IROND-L: study protocol for a French prospective, quasi-experimental, multicentre trial to examine the impact of a coordinated multidisciplinary approach for women victims of violenceFabienne El-Khoury, Inès Ben Ghezala, Ghada Hatem, et al.
BMJ Open|November 23, 2022
Combined incentive actions, focusing on primary care professionals, to improve cervical cancer screening in women living in socioeconomically disadvantaged geographical areas: a study protocol of a hybrid cluster randomised effectiveness and implementation trial- RESISTEAmir Hassine, Guillemette Antoni, Muriel Fender, et al.
Gut|May 18, 2019
Increasing incidence of colorectal cancer in young adults in Europe over the last 25 yearsFanny Er Vuik, Stella Av Nieuwenburg, Marc Bardou, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2004
SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm laborClaudine Serradeil-Le Gal, Gérard Valette, Loïc Foulon, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
The Journal of Pharmacology and Experimental Therapeutics|March 14, 2007
In vitro and in vivo pharmacological characterization of ethyl-4-[trans-4-[((2S)-2-hydroxy-3-[4-hydroxy-3[(methylsulfonyl)amino]-phenoxy]propyl) amino]cyclohexyl]benzoate hydrochloride (SAR150640), a new potent and selective human beta3-adrenoceptor agonist for the treatment of preterm laborTiziano Croci, Roberto Cecchi, Pietro Marini, et al.
BMC Proceedings|August 28, 2025
Accelerating HPV-related cancer elimination - a meeting reportF Ricardo Burdier, F Xavier Bosch, Dur-E-Nayab Waheed, et al.
European Journal of Medical Genetics|March 24, 2025
Lack of behavioural improvement with sirolimus in a patient with MTOR-related macrocephaly with pigmentary mosaicism: A new case reportBertille Bonniaud, Maxime Luu, Coline Cormier, et al.
The Pharmacogenomics Journal|May 19, 2022
Exome sequencing allows detection of relevant pharmacogenetic variants in epileptic patientsSimon Verdez, Quentin Thomas, Philippine Garret, et al.
Therapie|January 2, 2022
Health crisis: What opportunities for clinical drug research?Dominique Deplanque, Stanislas Cviklinski, Marc Bardou, et al.
Therapie|December 20, 2021
Dominique Deplanque, Stanislas Cviklinski, Marc Bardou, et al.
BMJ Open|November 20, 2024
IROND-L: study protocol for a French prospective, quasi-experimental, multicentre trial to examine the impact of a coordinated multidisciplinary approach for women victims of violenceFabienne El-Khoury, Inès Ben Ghezala, Ghada Hatem, et al.
BMJ Open|November 23, 2022
Combined incentive actions, focusing on primary care professionals, to improve cervical cancer screening in women living in socioeconomically disadvantaged geographical areas: a study protocol of a hybrid cluster randomised effectiveness and implementation trial- RESISTEAmir Hassine, Guillemette Antoni, Muriel Fender, et al.
Gut|May 18, 2019
Increasing incidence of colorectal cancer in young adults in Europe over the last 25 yearsFanny Er Vuik, Stella Av Nieuwenburg, Marc Bardou, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2004
SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm laborClaudine Serradeil-Le Gal, Gérard Valette, Loïc Foulon, et al.
Pageof 15